Background: Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab-exposed pregnancies (VDZE) are sparse.
| INTRODUC TI ON
Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are often diagnosed during the fertile period of life. This special situation must be taken into account when selecting an appropriate medical treatment. 1 Previous studies have shown that disease remission prior to conception and throughout pregnancy is crucial for favourable pregnancy outcomes. 2 In order to achieve disease remission, patients with IBD are frequently treated with biological therapies such as vedolizumab (VDZ), a monoclonal antibody directed against the α4β7 integrin-mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) interaction in the gut. [3] [4] [5] [6] By blocking this interaction, VDZ inhibits the trafficking of gut-homing lymphocytes. 3 However, data on the use of VDZ during conception and pregnancy remain sparse. [7] [8] [9] [10] [11] We previously reported several pregnancy and neonatal complications among female IBD patients treated with VDZ in a retrospective Belgian study. In particular, a relatively high number of congenital malformations were reported (three out of 23 live births: hip dysplasia, pulmonary valve stenosis and Hirschsprung's disease). Additionally, the published case of a congenital corpus callosum agenesis anomaly in a healthy volunteer exposed to VDZ gave rise to concerns. 7, 8 Since the Belgian study was too small to draw firm conclusions and underlying active disease was a major confounding factor, a pan-European study was performed to increase the number of VDZ-exposed (VDZE) pregnancies and thus the statistical power. The aim of the current study was to assess pregnancy and child outcomes in a larger cohort of women with IBD treated with VDZ in comparison to pregnancy outcomes in IBD patients treated with anti-tumour necrosis factor (anti-TNF) therapy or not treated with immunomodulators (IMs) nor biologics.
| MATERIAL S AND ME THODS

| Study population
This was a retrospective multicentre (n = 29) observational study, whereby European gastroenterologists were asked to report all VDZE pregnancies between March 2009 and December 2018. Further inclusion criteria were that infants had to be at least 3 months old at the time of inclusion in the study. A subset of this study population was already published in previous studies. 8, 12, 13 The control groups of anti-TNF-exposed (TNFE) and IMs and biologics unexposed (CON IBD) pregnancies were prospectively collected in collaboration with two centres with a specialised IBD pregnancy clinic (Erasmus Medical Center, Rotterdam, The Netherlands and Shaare Zedek Medical Centre, Jerusalem, Israel). Both centres were asked to enrol 100 consecutive patients per control group. The aim was to include around 100 VDZE pregnancies and twice as many TNFE and CON IBD pregnancies. Cases and controls were not matched.
| Ethical considerations
Data collection started after ethical approval by the Ethics Committee of the University Hospitals Leuven, Leuven, Belgium (S60985) and where necessary after ethical approval by a local committee for other centres.
| Data collection
Information from VDZE pregnancies was collected through a structured electronic case report form (CRF), adapted from the CRF used in the previous Belgian observational study, 8 and had to be filled out by the treating gastroenterologist ( Figure S1 ). To avoid missing data, gastroenterologists were requested to contact the patients, general practitioners, paediatricians or other colleagues.
Control centres were asked to contribute the same maternal and neonatal information. However, since these patients were already included in a prospective database prior to this study, not all variables were available.
| Outcomes
The aims of this study were (a) to assess the outcome of VDZE pregnancies both for the mother and the child and (b) to compare these results to outcomes of TNFE and CON IBD pregnancies. Primary and secondary outcome parameters included the number of live births, stillbirths, miscarriages and elective terminations, preterm deliveries, infections during pregnancy (including chorioamnionitis), (pre-) eclampsia, placenta praevia, IBD flare during pregnancy and neonatal complications such as IUGR, low birthweight, small for gestational age, low Apgar score at birth, congenital anomalies, admission to neonatal intensive care unit, serious infection or malignancy in the first year of life or at last follow-up.
| Definitions
Stillbirth was defined as foetal loss after 20 weeks post-conception. 14 Preterm delivery was defined as any delivery before 37 weeks of gestation. 15 Low birthweight was defined as a birthweight less than 2500 g in a child born at term. 15 Small for gestational age was defined as a weight below the 10th percentile with regard to gestational age 16 and a low Apgar score was defined as a score <7 at minute 5. 17 The first trimester was characterised as the time from conception until week 14 of gestation, the second trimester from week 14 to 28 and the third trimester from week 28 until delivery. Severe infectious complications in the newborn were regarded as infectious complications requiring or prolonging hospitalisation. IBD disease activity was retrospectively assessed at conception and during each trimester of pregnancy using PGA and patients' recorded disease activity. PGA options correspond to "active disease" or "remission" and were based on the clinical judgement of the treating gastroenterologist. Clinical remission for UC patients based on patients' recorded disease activity was based on patient-reported outcome (PRO2) scores and defined as a rectal bleeding score of 0 and an absolute number of stools ≤3, and for CD patients it was based on an abdominal pain score ≤1 and liquid to very soft stool frequency ≤1.5 for CD. 18 Due to a lot of missing patients' recorded scores in the VDZE group and the absence of these scores in the control groups, only PGA was used.
| Statistical analysis
Descriptive statistics were used to display the results. For discrete data, proportions and percentages were reported, whereas for continuous data medians with interquartile ranges (IQR) were presented. To compare cases and controls, we used Fisher's exact test or Chi-squared for categorical data and Mann-Whitney U test for continuous data. In case of missing data, these data were not included in the analyses. ibm spss Statistics 25.0 software package was used. A P < .05 was regarded as statistically significant. 
| RE SULTS
| Study population
| Maternal baseline characteristics
Baseline characteristics are displayed in Table 1 . Groups were comparable regarding age at conception and duration of underlying IBD, although the TNFE group included significantly more women with CD compared to the VDZE group (83% vs 55%, P = .0001). At conception, 27 (36%) VDZE women had clinically active disease according to PGA, 16 (20%) were on concomitant steroids and 14 (18%) on IMs. In addition, 42 (55%) previously failed two other biological treatments. Disease activity at conception and being on steroids were both significantly increased among the VDZE group compared to the TNFE (activity disease: 36% vs 17%, P = .002; steroid treatment: 20% vs 8%, P = .005) and the CON IBD groups (activity disease: 36% vs 24%, P = .063, and steroid treatment: 20% vs 14%, P = .195). The proportion of women who smoked or drank alcohol in pregnancy was comparable between groups, but the intake of folic acid supplementation was higher, though not significant, in the VDZE group compared to the TNFE group and CON IBD group.
| Medication use in pregnancy
| VDZE group (n = 79)
At conception, the median duration of VDZ therapy was 7 (IQR 3-12) months and 83% of VDZ-treated patients were on maintenance Abbreviations: CD, Crohn's disease; CON IBD, immunomodulatory or biologic unexposed pregnancies; IBD, inflammatory bowel disease; IMs, immunomodulators; IQR, interquartile range; PGA, physician global assessment; TNFE, anti-TNF-exposed pregnancies; VDZE, vedolizumab exposed pregnancies; UC, ulcerative colitis. Fixed variables were determined at the time of the first pregnancy (eg diagnosis CD or UC), while adjustable variables were determined for each pregnancy (eg disease activity). *means a P-value of <0.05 and thus a statistical signifcant result.
therapy with 300-mg intravenous VDZ every 4 weeks (Q4W, n = 21, 26%) or every 8 weeks (Q8W, n = 45, 57%). At gestational week 15, one of these patients underwent dose de-escalation (Q4W-Q8W) and at gestational week 20, another woman needed dose escalation (Q8W-Q4W). Ten patients (13%) received induction therapy at conception and three (4%) initiated VDZ treatment after conception. The latter included two patients who initiated VDZ treatment at gestational week 7, one in combination with mesalazine throughout pregnancy and one with corticosteroids for one trimester, after loss of response to adalimumab (ADM) and golimumab respectively. A third patient initiated VDZ treatment at gestational week 17 due to flare and this in combination with corticosteroids throughout pregnancy.
During pregnancy, the median number of administered VDZ infusions was 4 (IQR 2-5). For women with live born children, (n = 38, 62%) discontinued VDZ treatment in pregnancy, equivalent to 13 (20%) in the first, 21 (34%) in the second and 5 (8%) in the third trimester. Twentythree (38%) women continued VDZ therapy throughout pregnancy.
The reasons for stopping VDZ treatment were: advice of multidisciplinary consultation mainly because of unknown effects (n = 31, 78%), at the request of the patient (n =3, 8%), upon recommendation of the treating gastroenterologist (n = 2, 5%) or gynaecologist (n = 1, 2%), due to loss of response and need for colectomy (n = 1, 2%) and in two cases no reasoning was available (5%). After delivery, 34 (76%) women restarted VDZ treatment, two (4%) switched to anti-TNF therapy, three (7%) to UST, four (9%) patients did not restart therapy and another two (4%) received other treatments. The use of VDZ at conception and during pregnancy is shown in Figure 1 , whilst Figure 2 displays the use of concomitant medication during pregnancy.
| TNFE group (n = 186)
At conception, 84 (45%) were on infliximab (IFX) monotherapy, 101 (54%) on ADM monotherapy and the remaining patient (0.5%) initiated ADM treatment during the first trimester. In patients receiving IFX monotherapy, the following schedules were administered: 5 mg/ kg every 4 (n = 3, 4%), every 6 (n = 16, 19%), every 7 (n = 7, 8%), every 8 (n = 48, 57%) or every 9 (n = 2, 2%) weeks, two (2%) patients received 10 mg/kg every 6 or 8 weeks and six (7%) patients had an unknown treatment schedule. Twelve women (20%) discontinued their IFX treatment during the first trimester, 24 (39%) during the second trimester and eight (13%) during the third trimester. Patients who received their last IFX infusion before gestational week 32 were considered as discontinuing IFX therapy in pregnancy. Seventeen (28%) patients continued IFX treatment throughout pregnancy.
Treatment regimens for ADM included the following: 40 mg/kg every other week (n = 71, 70%), every week (n = 25, 25%) or unknown (n = 5, 5%). ADM was discontinued in the first, second or third trimester in six (8%), 23 (32%) and 13 (18%) patients respectively. Patients receiving their last ADM injection before gestational week 36 were considered as discontinuing ADM therapy in pregnancy. The remaining 17 (23%) patients received ADM treatment throughout pregnancy.
Of note, the most frequent reason for discontinuing anti-TNF therapy in pregnancy was disease remission. Usage of concomitant therapy is shown in Figure 3 .
| CON IBD group
The CON IBD group consisted of pregnancies that were not exposed to biologics nor to immunomodulatory drugs. At conception, 92 (50%) females were being treated with mesalazine monotherapy, 12 (7%) with monotherapy of steroids, 12 (7%) with a combination of mesalazine and steroids and the remaining 67 patients (36%) did not receive any IBD therapy. Of the 24 (13%) women on steroids, 21 (88%) continued this therapy during the course of pregnancy.
| Pregnancy outcomes and complications
In the VDZE group, 68% of women (n = 54) had been pregnant before and 41% (n = 22) of these previous pregnancies were complicated by PROM (n = 3, 14%), miscarriage (n = 14, 64%), ectopic pregnancy (n = 1, 4%), IBD flare (n = 2, 9%) or other complications (n = 2, 9%).
In the TNFE group, 68 women (42%) had a prior pregnancy of which The rate of live-born infants was high (VDZE: 78%, TNFE: 87% and CON IBD: 89%), not significantly different between the VDZE and TNFE groups (P = .103), though significantly higher in the CON IBD group compared to the VDZE group (P = .038) ( Figure S2 ).
Excluding patients with active disease at any point in pregnancy resulted in similar rates of live born children in the VDZE group compared to the TNFE (82% vs 83%, P = .816) and the CON IBD (82% vs 85%, P = .617) groups respectively.
In addition, there was no difference in miscarriage rates between the VDZE and TNFE groups (16% vs 13%, P = .567) nor between VDZE and CON IBD groups (16% vs 10%, P = .216). The proportion of elective terminations was significantly higher in cases compared to controls: VDZE vs TNFE (5% vs 0%, P = .007) and CON IBD (5% vs 0.5%, P = .030). Overall, the number of stillbirths was low and did not differ between the VDZE and TNFE groups (1% vs 0%, P = .298) nor the VDZE and CON IBD groups (1% vs 0%, P = .300). When looking only at women with disease remission throughout pregnancy, no difference in the amount of miscarriages was seen in the controls compared to cases (VDZE vs TNFE [16% vs 17%, P = 1.000]; VDZE vs CON IBD [16% vs 15%, P = .799], Figure S3 ).
Other complications in the VDZE group include PROM (n = 3, all occurred before GW37), IUGR (n = 2), pre-eclampsia (n = 3), placenta praevia (n = 1), maternal catheter-related sepsis (n = 1) and intraventricular neonatal bleeding (n = 1).
| Infants' baseline characteristics and neonatal complications
Neonatal outcomes are displayed in Table 2 . In live-born infants, median gestational age and birthweight were similar between groups.
Median Apgar score at birth was also numerically equal in all groups.
The number of premature born infants was similar in the VDZE group compared to the TNFE (16% vs 9%, P = .151) and CON IBD groups (16% vs 7%, P = .079), even after correcting for disease activity in pregnancy (VDZE: 8% vs TNFE: 4%, P = .363; VDZE: 8% vs CON IBD: 6%, P = .687) ( Figure S4 ). The amount of reported congenital anomalies in live-born children was comparable between groups (VDZE: 5% vs TNFE: 2%, P = .407; VDZE: 5% vs CON IBD: 2%, P = .354) ( Table 3) .
F I G U R E 2 Use of concomitant medication in vedolizumab-exposed pregnancies. Trimester 1: exclusion of 12 early miscarriages and three elective terminations. In the TNFE group, one case of Down syndrome was reported, but this pregnancy was terminated electively. The percentages of breastfed babies (VDZE: 62% vs TNFE: 60%, P = .877; VDZE: 62% vs CON IBD: 64%, P = .875) were similar in all groups. Regarding vaccination, information was only available for the VDZE group in which all children (for whom information was available, n = 60) followed the national immunisation programme with the exception of the administration of live attenuated vaccines. The latter were given in 17 (28%) of these infants and include Rotavirus (n = 14) and/or Bacillus Calmette-Guérin vaccine (n = 3). No adverse reactions to vaccinations were reported. During the first year of life, no malignancies were reported and the infants' infection risk did not significantly differ between groups (VDZE: 5% vs TNFE: 10%, P = .326; VDZE: 5% vs CON IBD: 12%, P = .193). Table 4 summarises the reported serious infections in each group.
| D ISCUSS I ON
This is the largest study to date to report on pregnancy outcomes in IBD patients treated with VDZ. Furthermore, it is the first study to compare these results to pregnancy outcomes of women treated with anti-TNF therapy or without IM/biological therapy.
The pregnancy outcomes of our study were favourable with an overall high rate of live births in all groups, though the number of live born infants was significantly higher in the CON IBD group compared to the VDZE group. This is probably due to the higher number of patients with active disease in the VDZE group since the difference in live born infants between both groups disappeared after excluding patients with active disease in pregnancy. Since MAdCAM-1 is expressed in the human placenta during the first trimester of pregnancy, 19 concerns have been raised about a theoretical risk of early miscarriage with the use of VDZ during conception and pregnancy. However, in this cohort of 79 VDZ-exposed pregnancies, there was no significant difference in the number of miscarriages between the VDZE group and the TNFE or CON IBD group.
Furthermore, the percentage of stillbirths was low in all groups.
No dissimilarities were observed between groups with respect to infants' baseline characteristics. Concerning the vaccination status of infants, no comparison could be made due to lack of data from the control patients. The study revealed a high rate of vaccination in the VDZE infants. Almost one-third of babies received one or more live attenuated vaccine of whom seven children were exposed to VDZ until the first trimester, nine until the second trimester and two until the 30th week of gestation. No adverse events after vaccination were reported. The rate of vaccination in our cohort is comparable to previous cohorts of TNFE children, though the administration rate of live attenuated vaccines was lower in our cohort. [20] [21] [22] [23] Overall, the risk of adverse pregnancy outcome was similar within the three groups. Furthermore, the risk of congenital anomalies was low, and comparable among the three groups. The low risk of adverse pregnancy outcome in the present study is in line with previous studies among TNFE and nonbiological therapy-exposed infants born by mothers with IBD. 7, 20, 24, 25 The present study verifies the findings of a large prospective
Dutch study that remission in IBD prior to conception and throughout pregnancy is the most import factor to achieve favourable pregnancy outcomes, irrespective of the IBD medication prescribed. 26 As such, focus should remain on the preconception and pregnancy counselling.
We acknowledge several limitations of the current study. First, the VDZE cases and controls (TNFE and CON IBD) were not entirely comparable. The VDZE group was more refractory than the TNFE and the CON IBD groups. More than half of the VDZE group had previously been treated with two other biologicals. Furthermore, at conception, the likelihood of active disease and steroid use was increased in the VDZE population. Moreover, among VDZE CD patients, extensive disease, stricturing or fistulising phenotype and perianal involvement were more frequent. Finally, the two control groups (TNFE and CON IBD) were collected in two independent centres with a specialised IBD pregnancy clinic that includes standardised preconception consultation and pregnancy monitoring, whereas the follow-up of VDZE pregnancies varied according to standard clinical practice at each participating centre. Overall, the variation in underlying disease severity and differences in recruitment policy may have affected our relative estimates. 27 Second, information on VDZE pregnancies was retrospectively acquired, therefore a certain degree of selection bias cannot be excluded. On the other hand, data on controls were prospectively attained prior to the present study resulting in some variables being absent. Last, disease activity was based on PGA as collection of disease activity scores such as PRO2 was incomplete and could therefore not be used to confirm disease activity.
| CON CLUS ION
This is the largest European study to date to report on pregnancy outcomes in VDZ-treated IBD patients and to compare these results with women treated either with anti-TNF therapy or without IM and biological therapy. The risk of adverse pregnancy outcome was low in all three groups. After excluding patients with reported active disease at any point in pregnancy, the number of miscarriages was similar in all groups. In addition, the use of VDZ could not be associated with an increased risk of major congenital anomalies in the offspring. The use of VDZ during conception and pregnancy seems to convey a low risk, although this still needs to be confirmed by large, prospective trials. Polydactyly 1°1
Syndactyly 1
Abbreviations: CON IBD: immunomodulatory and biologic unexposed; TNFE: anti-TNF-exposed; VDZE: vedolizumab exposed. a Only in children born alive. Child was exposed to methotrexate at conception. Acute otitis media 1
TA B L E 4 Serious infections
Fever of unknown origin 1 1 1
Kawasaki's disease 1
Pyelonephritis 1
Respiratory tract infection 1 1
Unknown 2 5
Urinary tract infection 2 Abbreviations: CON IBD, immunomodulatory and biologic unexposed; TNFE, anti-TNF-exposed; VDZE, vedolizumab exposed. a Only children born alive and defined as infections for which the child required hospitalisation.
